Literature DB >> 21447799

Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.

Liudmilla Rubbi1, Björn Titz1, Lauren Brown1, Erica Galvan1, Evangelia Komisopoulou1, Sharon S Chen1, Tracey Low1, Martik Tahmasian1, Brian Skaggs2, Markus Müschen3, Matteo Pellegrini4,5, Thomas G Graeber1,5.   

Abstract

In subtypes and late stages of leukemias driven by the tyrosine kinase fusion protein Bcr-Abl, signaling by the Src family kinases (SFKs) critically contributes to the leukemic phenotype. We performed global tyrosine phosphoprofiling by quantitative mass spectrometry of Bcr-Abl-transformed cells in which the activities of the SFKs were perturbed to build a detailed context-dependent network of cancer signaling. Perturbation of the SFKs Lyn and Hck with genetics or inhibitors revealed Bcr-Abl downstream phosphorylation events either mediated by or independent of SFKs. We identified multiple negative feedback mechanisms within the network of signaling events affected by Bcr-Abl and SFKs and found that Bcr-Abl attenuated these inhibitory mechanisms. The C-terminal Src kinase (Csk)-binding protein Pag1 (also known as Cbp) and the tyrosine phosphatase Ptpn18 both mediated negative feedback to SFKs. We observed Bcr-Abl-mediated phosphorylation of the phosphatase Shp2 (Ptpn11), and this may contribute to the suppression of these negative feedback mechanisms to promote Bcr-Abl-activated SFK signaling. Csk and a kinase-deficient Csk mutant both produced similar globally repressive signaling consequences, suggesting a critical role for the adaptor protein function of Csk in its inhibition of Bcr-Abl and SFK signaling. The identified Bcr-Abl-activated SFK regulatory mechanisms are candidates for dysregulation during leukemia progression and acquisition of SFK-mediated drug resistance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447799      PMCID: PMC4057100          DOI: 10.1126/scisignal.2001314

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  72 in total

Review 1.  The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway.

Authors:  Marie Dance; Alexandra Montagner; Jean-Pierre Salles; Armelle Yart; Patrick Raynal
Journal:  Cell Signal       Date:  2007-10-11       Impact factor: 4.315

Review 2.  Alignment of LC-MS images, with applications to biomarker discovery and protein identification.

Authors:  Mathias Vandenbogaert; Sébastien Li-Thiao-Té; Hans-Michael Kaltenbach; Runxuan Zhang; Tero Aittokallio; Benno Schwikowski
Journal:  Proteomics       Date:  2008-02       Impact factor: 3.984

3.  A quantitative analysis software tool for mass spectrometry-based proteomics.

Authors:  Sung Kyu Park; John D Venable; Tao Xu; John R Yates
Journal:  Nat Methods       Date:  2008-03-16       Impact factor: 28.547

Review 4.  An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data.

Authors:  Lukas N Mueller; Mi-Youn Brusniak; D R Mani; Ruedi Aebersold
Journal:  J Proteome Res       Date:  2008-01-04       Impact factor: 4.466

5.  A quantitative analysis of kinase inhibitor selectivity.

Authors:  Mazen W Karaman; Sanna Herrgard; Daniel K Treiber; Paul Gallant; Corey E Atteridge; Brian T Campbell; Katrina W Chan; Pietro Ciceri; Mindy I Davis; Philip T Edeen; Raffaella Faraoni; Mark Floyd; Jeremy P Hunt; Daniel J Lockhart; Zdravko V Milanov; Michael J Morrison; Gabriel Pallares; Hitesh K Patel; Stephanie Pritchard; Lisa M Wodicka; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2008-01       Impact factor: 54.908

6.  Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Authors:  Ji Wu; Feng Meng; Ling-Yuan Kong; Zhenghong Peng; Yunming Ying; William G Bornmann; Bryant G Darnay; Betty Lamothe; Hanshi Sun; Moshe Talpaz; Nicholas J Donato
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

7.  The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src.

Authors:  Chitose Oneyama; Tomoya Hikita; Kengo Enya; Marc-Werner Dobenecker; Kazunobu Saito; Shigeyuki Nada; Alexander Tarakhovsky; Masato Okada
Journal:  Mol Cell       Date:  2008-05-23       Impact factor: 17.970

Review 8.  Src family kinases: regulation of their activities, levels and identification of new pathways.

Authors:  Evan Ingley
Journal:  Biochim Biophys Acta       Date:  2007-08-22

Review 9.  Therapy options in imatinib failures.

Authors:  Pablo Ramirez; John F DiPersio
Journal:  Oncologist       Date:  2008-04

10.  Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation.

Authors:  Panagis Filippakopoulos; Michael Kofler; Oliver Hantschel; Gerald D Gish; Florian Grebien; Eidarus Salah; Philipp Neudecker; Lewis E Kay; Benjamin E Turk; Giulio Superti-Furga; Tony Pawson; Stefan Knapp
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

View more
  30 in total

1.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 2.  Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Authors:  Justin M Drake; John K Lee; Owen N Witte
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

3.  BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.

Authors:  Kenta Moriyama; Toshiyuki Hori
Journal:  Int J Hematol       Date:  2019-08-19       Impact factor: 2.490

4.  Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.

Authors:  J A Cutler; R Tahir; S K Sreenivasamurthy; C Mitchell; S Renuse; R S Nirujogi; A H Patil; M Heydarian; X Wong; X Wu; T-C Huang; M-S Kim; K L Reddy; A Pandey
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

5.  Complexity of metastasis-associated SDF-1 ligand signaling in breast cancer stem cells.

Authors:  Nicholas A Graham; Thomas G Graeber
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-14       Impact factor: 11.205

Review 6.  Protein networks and activation of lymphocytes.

Authors:  Ynes A Helou; Arthur R Salomon
Journal:  Curr Opin Immunol       Date:  2015-02-14       Impact factor: 7.486

7.  TSLP signaling network revealed by SILAC-based phosphoproteomics.

Authors:  Jun Zhong; Min-Sik Kim; Raghothama Chaerkady; Xinyan Wu; Tai-Chung Huang; Derese Getnet; Christopher J Mitchell; Shyam M Palapetta; Jyoti Sharma; Robert N O'Meally; Robert N Cole; Akinori Yoda; Albrecht Moritz; Marc M Loriaux; John Rush; David M Weinstock; Jeffrey W Tyner; Akhilesh Pandey
Journal:  Mol Cell Proteomics       Date:  2012-02-16       Impact factor: 5.911

Review 8.  Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Anna M Eiring; Michael W Deininger
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

Review 9.  Is phosphoproteomics ready for clinical research?

Authors:  Anton B Iliuk; W Andy Tao
Journal:  Clin Chim Acta       Date:  2012-11-13       Impact factor: 3.786

10.  Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.

Authors:  Koshi Imami; Naoyuki Sugiyama; Haruna Imamura; Masaki Wakabayashi; Masaru Tomita; Masatoshi Taniguchi; Takayuki Ueno; Masakazu Toi; Yasushi Ishihama
Journal:  Mol Cell Proteomics       Date:  2012-09-10       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.